TVTX

Travere Therapeutics Inc.

Price

$56.50

return (12m)

129.30%

p/e

-121.52

p/bv

215.38

DIVIDEND YIELD

0.00%

TVTX price

Travere Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TVTX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-13.95%

3 months

-1.90%

1 year

129.30%

2 years

313.92%

5 years

122.53%

10 years

145.12%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals TVTX

Valuation

P/E

-121.52

Sector -3.46

Industry -3.46

P/BV

215.38

Sector 1.94

Industry 1.94

P/Revenue (PSR)

8.93

Sector 1.96

Industry 1.96

EV/EBITDA

-167.37

Sector -216.42

Industry -216.42

EV/EBIT

-145.81

Sector -46.11

Industry -46.11

P/EBITDA

914.09

Sector -21.02

Industry -21.02

P/EBIT

-91.71

Sector -27.60

Industry -27.60

P/Total Assets

6.61

Sector 1.14

Industry 1.14

P/Net Current Assets

-33.07

Sector -10.24

Industry -10.24

P/Working Capital

11.40

Sector -162.19

Industry -162.19

EPS

-0.46

Sector -1.78

Industry -1.78

BVPS

0.26

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

98.60%

Sector 41.35%

Industry 41.35%

EBITDA Margin

-16.88%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

-19.38%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

-6.84%

Sector -35.47%

Industry -35.47%

Net Profit Margins

-7.35%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.21

Sector 0.03

Industry 0.03

Profitability

ROE

-177.24%

Sector -57.40%

Industry -57.40%

ROA

-5.44%

Sector -59.43%

Industry -59.43%

ROIC

7.62%

Sector -2,370.21%

Industry -2,370.21%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.05

Sector 2.91

Industry 2.91

Net Debt / EBITDA

17.08

Sector -21.98

Industry -21.98

Net Debt / EBIT

14.88

Sector -8.44

Industry -8.44

Net Debt / Equity

-19.95

Sector -33,112.99

Industry -33,112.99

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.03

Sector 0.46

Industry 0.46

Liabilities/Assets

0.97

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

35.01%

Sector -

Industry -

5Y Earnings CAGR

-24.75%

Sector -

Industry -

Fundamentals TVTX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TVTX Travere Therapeutics Inc.	$56.50	127.91%	0.00%	-121.52	215.38	-177.24%	-7.35%
PFE Pfizer Inc.	$27.48	8.11%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$259.97	9.77%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$37.23	-33.47%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$143.18	65.09%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$156.59	-4.79%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.33	34.59%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$69.46	-51.82%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$402.15	38.44%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$729.88	22.13%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$108.98	45.42%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$888.29	16.56%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$501.27	24.01%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$226.17	45.05%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$914.13	19.13%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$39.41	46.40%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$220.34	42.87%	0.00%	38.99	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TVTX - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Travere Therapeutics

Travere Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

15 years

Founded: 2011

2003

Time since IPO - 23 years

262

Employees

Travere Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $5.28 billion, with shareholders equity totaling $24.52 million.

The company employs approximately 262 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Travere Therapeutics Inc. reported $591.33 million in revenue, generating net income of $-43.46 million.

Key financial metrics include a P/E ratio of -121.52, a price-to-book (P/B) ratio of 215.38, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TVTX.

Market cap

$5.28 billion

Net worth

$24.52 million

$24,522,000.00

Assets

$799.36 million

$799,360,000.00

Total Shares Outstanding

93.48 million

93,479,000

Average Daily Trading Volume

$1.59 million

$1,592,376.00

Sector

Health Care

Industry

Biotechnology

TVTX

TVTX revenue and profits

Financial Results TVTX

DRAG THE FRAME TO SEE MORE DATA

TVTX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$888.29 20,83% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$226.17 47,96% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$259.97 14,69% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$143.18 65,85% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$156.59 --6,84% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$27.48 7,47% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$888.29 20,83% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$226.17 47,96% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$259.97 14,69% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$143.18 65,85% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$156.59 --6,84% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$27.48 7,47% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$60.33 39,02% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of Travere Therapeutics (TVTX) today?

The current price of Travere Therapeutics (TVTX) is $56.50. The stock began the year trading around $38.21 and is currently priced at $56.50. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Travere Therapeutics (TVTX) pay dividends?

Travere Therapeutics (TVTX) did not pay dividends over the past year.

Is Travere Therapeutics (TVTX) a good investment?

Travere Therapeutics (TVTX) is currently trading at $56.50 with a P/E ratio of -121.52. This represents a -5,403% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 129.30%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Travere Therapeutics (TVTX) stock?

You can buy Travere Therapeutics (TVTX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol TVTX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Travere Therapeutics (TVTX) yield today?

Over the past month, Travere Therapeutics (TVTX) has returned -13.95% — 129.30% over the past year, and 122.53% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Travere Therapeutics (TVTX) today at the current price of $56.50 your total investment would be $5,650.00.

Based on historical performance, the investment would have grown to approximately:

$12,955.45 after 1 year
$12,572.95 after 5 years
$13,849.28 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

TVTX

Travere Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TVTX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING TVTX WITH OTHER STOCK

ABOUT Travere Therapeutics

Travere Therapeutics Inc.

United States

15 years

2003

262

PROFIT X PRICE TVTX

Financial Results TVTX

TVTX cash flow

Asset, Revenue and Profit Growth - TVTX

TVTX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions